HealthMore in Health→
AstraZeneca's Oral GLP-1 Pill Shows Promise in Mid-Stage Obesity and Diabetes Trials
Key Takeaways
- AstraZeneca's oral GLP-1 pill showed 12% average weight loss in Phase 2 obesity trial.
- Diabetes patients achieved significant HbA1c reductions with the once-daily pill.
- Safety profile consistent with GLP-1 class; GI side effects mild to moderate.
- Analysts say it's too early to compare with Novo Nordisk's Rybelsus or Lilly's orforglipron.
DE
DT Editorial Team··via statnews.com
